Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer
- PMID: 22472462
- DOI: 10.1016/j.ygyno.2012.03.044
Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer
Abstract
Background: Prognosis in advanced ovarian cancer is largely determined by completeness of tumor resection achieved during primary surgery. Incomplete initial debulking occurs frequently in non-specialized centers and there is an ongoing discussion about the best time for re-surgery after referral to tertiary centers.
Methods: Patients with advanced epithelial ovarian cancer (FIGO IIIB-IV) admitted between 1999 and 2007 who had primary incomplete surgery including those with initiated chemotherapy at an outside institution were included. Surgical results, morbidity and prognosis were evaluated in patients with immediate re-operation before chemotherapy and those with interval debulking.
Results: 48 eligible patients were identified in our tumor registry. Self-referral by patient was the most frequent mode of admission (n=21, 43.8%). 22 patients (45.8%) underwent immediate re-surgery and 26 patients (54.2%) had an interval debulking after chemotherapy. In 12 patients (54.5%), macroscopically complete tumor removal could be achieved by immediate re-operation and in 17 patients (65.4%) after chemotherapy. Major complications were observed more frequently in patients with interval debulking (26.9 vs. 9.1%, p=0.324). Median overall survival time was 53 and 34 months (p=0.110) after immediate and delayed re-operation, respectively.
Conclusions: Upfront re-operation before start of chemotherapy is feasible and successful in an expertise referral center in more than half of patients with incomplete primary surgery elsewhere. Complete resection even after initial incomplete debulking could improve outcome. Therefore, referral to expertise centers in those patients should be considered. Progression-free survival and overall survival showed a non-significant trend and complication rate is a remarkable advantage in favor of upfront re-operation.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Initial incomplete surgery modifies prognosis in advanced ovarian cancer regardless of subsequent management.Anticancer Res. 2015 Apr;35(4):2315-20. Anticancer Res. 2015. PMID: 25862895
-
[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Zhonghua Fu Chan Ke Za Zhi. 2012. PMID: 22883524 Chinese.
-
A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.Jpn J Clin Oncol. 2016 Jun;46(6):517-21. doi: 10.1093/jjco/hyw029. Epub 2016 Mar 13. Jpn J Clin Oncol. 2016. PMID: 26977055
-
Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.Curr Treat Options Oncol. 2016 Jan;17(1):1. doi: 10.1007/s11864-015-0380-2. Curr Treat Options Oncol. 2016. PMID: 26714493 Review.
-
Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.Oncology. 2016;91(4):211-216. doi: 10.1159/000447743. Epub 2016 Aug 3. Oncology. 2016. PMID: 27487241 Review.
Cited by
-
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study.Br J Cancer. 2014 Oct 14;111(8):1519-25. doi: 10.1038/bjc.2014.443. Epub 2014 Sep 16. Br J Cancer. 2014. PMID: 25225907 Free PMC article. Clinical Trial.
-
The Role of Completion Surgery in Ovarian Cancer.J Obstet Gynaecol India. 2016 Oct;66(Suppl 1):435-40. doi: 10.1007/s13224-015-0796-4. Epub 2015 Nov 4. J Obstet Gynaecol India. 2016. PMID: 27651643 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical